Biotech Values

[DewDiligence]

BIIB ELN:

Tysabri sales are accelerating

In the US market (which is what I’m concerned about as a MNTA long), Tysabri’s growth rate has been anemic at best. The most recent four quarters of US sales of Tysabri and Copaxone are as follows:

 
       Tysabri    Copaxone 
      sales ($M) sales ($M) 
 2Q09    125         * 
 1Q09    116        430 
 4Q08    115        384 
 3Q08    122        352 

Thus, the cumulative growth in US Tysabri sales over the past three quarters has been 2.5%, which works out to an annualized growth rate of only 3-4%.

*Teva reports 2Q09 results on Jul 29. Much to srsmgja’s chagrin, it’s a pretty good bet that Copaxone will continue cleaning Tysabri’s clock in the US market.